Impact of sarcopenia on the prognosis of patients with advanced non‐small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Fuchun Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Sarcopenia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Novel Clinical Diagnosis and Treatment Technology Research Project of Nantong City.
Abstract (Originalsprache)
Background
Limited information is available regarding the impact of sarcopenia on the prognosis of antiangiogenic therapy in individuals with advanced non‐small cell lung cancer (NSCLC). This study primarily sought to examine the prognostic significance of sarcopenia in individuals with advanced NSCLC undergoing antiangiogenic therapy.
Methods
We retrospectively enrolled all patients who met the inclusion and exclusion criteria from 2019 to 2021 at Nantong University Hospital. Patients were grouped according to the presence or absence of sarcopenia. After propensity score matching (PSM), progression‐free survival (PFS), overall survival (OS), and adverse event rates were compared between the two groups. Factors associated with prognosis were screened using univariate and multivariate analyses.
Results
A total of 267 patients were included, with a total of 201 matched at baseline after PSM (77 in the sarcopenia group and 124 in the non‐sarcopenia group). The sarcopenia group had lower PFS ( p = 0.043) and OS ( p = 0.011) than the non‐sarcopenia group and a higher incidence of adverse events ( p = 0.044). Multivariate analysis suggested that sarcopenia is an independent prognostic risk factor for OS in advanced NSCLC patients receiving antiangiogenic therapies ( p = 0.009). Results of subgroup analyses showed some differences in the impact of sarcopenia on survival prognosis in populations with different characteristics.
Conclusion
Patients with advanced NSCLC with comorbid sarcopenia exhibit a worse prognosis when treated with antiangiogenic therapy, and preventing and ameliorating sarcopenia may lead to better survival outcomes in patients with advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
ORCID-Profile: Shuang Yang, Hua Liu
Förderung
- National Natural Science Foundation of China
- Novel Clinical Diagnosis and Treatment Technology Research Project of Nantong City
Zitieren
APA
Huang, F., Ma, M., Lang, L., Yang, S., Zhao, H., Zhang, J., & Liu, H. (2024). Impact of sarcopenia on the prognosis of patients with advanced non‐small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15443
Vancouver
Huang F, Ma M, Lang L, Yang S, Zhao H, Zhang J, et al. Impact of sarcopenia on the prognosis of patients with advanced non‐small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15443
BibTeX
@article{Huang2024,
author = {Huang, Fuchun and Ma, Mingxuan and Lang, Liye and Yang, Shuang and Zhao, Hui and Zhang, Jialin and Liu, Hua},
title = {Impact of sarcopenia on the prognosis of patients with advanced non‐small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15443}
}
EUVIMED